MIRA Pharmaceuticals Submits Phase 2a Protocol for Ketamir-2 in CIPN to FDA
MIRA is trading near its 52-week low of $0.9 (5.4% above the low).
Summary
MIRA Pharmaceuticals has advanced its lead drug candidate, Ketamir-2, by submitting a Phase 2a clinical trial protocol to the FDA for chemotherapy-induced peripheral neuropathy, a condition with no approved treatments.
Key Events · Product Development and Regulatory · MIRA
-
Phase 2a Protocol Submission
MIRA Pharmaceuticals submitted a Phase 2a clinical trial protocol for Ketamir-2 to the FDA for chemotherapy-induced peripheral neuropathy (CIPN).
-
FDA Acknowledgment Received
The company received formal acknowledgment from the FDA confirming acceptance of the Phase 2a clinical trial protocol submission (Protocol Mira-002).
-
Addresses Unmet Medical Need
Ketamir-2 targets CIPN, a debilitating condition affecting cancer patients for which there are currently no FDA-approved therapies.
-
Advancement of Lead Candidate
This marks a significant step in advancing Ketamir-2, following positive unblinded Phase 1 results and the securing of worldwide licensing rights for the drug.
Analysis · MIRA · Life Sciences
This 8-K announces MIRA Pharmaceuticals has submitted its Phase 2a clinical trial protocol for Ketamir-2, targeting chemotherapy-induced peripheral neuropathy (CIPN), to the FDA and received acknowledgment. This is a critical advancement for the company's lead drug candidate, especially given the high unmet medical need for CIPN, which currently lacks FDA-approved treatments. Progress in its clinical pipeline is vital for the company, which recently issued a going concern warning.
At the time of this filing, MIRA was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $39.9M. The 52-week trading range was $0.90 to $2.45. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.